Blueprint Medicines Co. (NASDAQ:BPMC) Given Consensus Recommendation of “Moderate Buy” by Analysts

Shares of Blueprint Medicines Co. (NASDAQ:BPMC) have been given a consensus rating of “Moderate Buy” by the twenty-three analysts that are covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, six have given a hold rating, fifteen have assigned a buy rating and one has given a strong buy rating to the company. The average 12-month price objective among brokers that have updated their coverage on the stock in the last year is $124.95.

Several research firms have recently commented on BPMC. Stephens restated an “overweight” rating and issued a $140.00 price objective on shares of Blueprint Medicines in a research note on Thursday, January 2nd. JPMorgan Chase & Co. upped their price target on Blueprint Medicines from $126.00 to $129.00 and gave the stock an “overweight” rating in a research report on Tuesday, February 4th. StockNews.com cut Blueprint Medicines from a “hold” rating to a “sell” rating in a research report on Monday, March 3rd. Scotiabank started coverage on Blueprint Medicines in a research note on Friday, March 7th. They set a “sector outperform” rating and a $150.00 price objective for the company. Finally, Wedbush restated an “outperform” rating and set a $128.00 target price on shares of Blueprint Medicines in a research note on Friday, February 28th.

Blueprint Medicines Trading Up 2.1 %

Blueprint Medicines stock opened at $82.53 on Tuesday. The business has a 50-day simple moving average of $90.36 and a two-hundred day simple moving average of $93.47. Blueprint Medicines has a 52-week low of $73.04 and a 52-week high of $121.90. The company has a quick ratio of 2.80, a current ratio of 2.85 and a debt-to-equity ratio of 1.15. The company has a market cap of $5.27 billion, a P/E ratio of -76.42 and a beta of 0.75.

Blueprint Medicines (NASDAQ:BPMC) last announced its earnings results on Thursday, February 20th. The biotechnology company reported ($0.79) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.68) by ($0.11). Blueprint Medicines had a negative net margin of 13.19% and a negative return on equity of 77.49%. Analysts predict that Blueprint Medicines will post -1.28 EPS for the current year.

Insider Buying and Selling at Blueprint Medicines

In related news, CEO Kate Haviland sold 1,446 shares of the business’s stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $110.24, for a total value of $159,407.04. Following the sale, the chief executive officer now owns 149,378 shares in the company, valued at approximately $16,467,430.72. The trade was a 0.96 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Ariel Hurley sold 3,203 shares of the company’s stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $92.62, for a total transaction of $296,661.86. Following the sale, the insider now directly owns 18,270 shares in the company, valued at approximately $1,692,167.40. The trade was a 14.92 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 24,358 shares of company stock valued at $2,583,187 in the last 90 days. Insiders own 4.21% of the company’s stock.

Institutional Trading of Blueprint Medicines

Large investors have recently made changes to their positions in the business. Avoro Capital Advisors LLC bought a new position in shares of Blueprint Medicines in the 4th quarter valued at about $103,356,000. Norges Bank purchased a new stake in Blueprint Medicines during the fourth quarter valued at approximately $62,028,000. Jennison Associates LLC purchased a new stake in Blueprint Medicines during the fourth quarter valued at approximately $31,417,000. Rock Springs Capital Management LP lifted its stake in shares of Blueprint Medicines by 42.7% in the 4th quarter. Rock Springs Capital Management LP now owns 1,096,899 shares of the biotechnology company’s stock valued at $95,672,000 after purchasing an additional 328,123 shares during the last quarter. Finally, Wellington Management Group LLP boosted its holdings in shares of Blueprint Medicines by 8.0% in the 4th quarter. Wellington Management Group LLP now owns 4,281,364 shares of the biotechnology company’s stock worth $373,421,000 after purchasing an additional 316,754 shares during the period.

Blueprint Medicines Company Profile

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.